Meng-Hua Tao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Meng-Hua Tao has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Loralee B. Rupp
Center for Health Policy and Health Services Research, Henry Ford Health, Detroit, Michigan
8 shared publications - Mark A. Schmidt
Kaiser Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, OR 97227, USA
8 shared publications - Mei Lu
School of Medicine Michigan State University East Lansing Michigan USA
8 shared publications - Sheri Trudeau
Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan
8 shared publications - Stuart C. Gordon
Division of Gastroenterology and Hepatology Henry Ford Health Detroit Michigan USA
8 shared publications - Trueman Wu
Department of Public Health Sciences Henry Ford Health Detroit Michigan USA
8 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Springer Nature in European Journal of Nutrition
- Vol. 65 (5) , 172
Association of food insecurity with metabolic dysfunction-associated steatotic liver disease by sex and race/ethnicity
Purpose: We examined whether the association between food insecurity and metabolic dysfunction-associated steatotic liver disease (MASLD) differs across different racial/ethnic groups and sex using data from the 2017–March 2020 National Health and Nutrition Examination Survey (NHANES). Methods: A total of 5076 participants aged ≥ 20 years who completed transient elastography examination for evaluation of MASLD were included. Logistic regression, odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate the association of food insecurity with MASLD. Results: Adult food insecurity was associated with increased odds of MASLD (low/very low vs. full security: OR = 1.41, 95% CI 1.12–1.77). Although there was no significant interaction between food insecurity and race/ethnicity ( p interaction = 0.23), the positive association between food insecurity and MASLD was limited among non-Hispanic Whites. Food insecurity was associated with higher odds of MASLD in women but not men, with an interaction between food insecurity and sex ( p interaction = 0.049). Furthermore, mediation analyses suggested that added sugar intake and intake of whole fruits and non-potato vegetables partially mediated the association of food insecurity with MASLD. The partial mediating effects of these foods were observed only among non-Hispanic Whites but not observed in other racial/ethnic groups or across sex. Conclusion: Our results suggest that the positive association between food insecurity and MASLD may be dependent on race/ethnicity and sex. Increased consumption of whole fruits vegetables intake and reduced intake of added sugar may partially reduce the impact of food insecurity on MASLD development.
- 19 June 2026
- Published by Springer Nature in European Journal of Nutrition
- Vol. 65 (5) , 172
Open AccessAssociation of food insecurity with metabolic dysfunction-associated steatotic liver disease by sex and race/ethnicity
Purpose: We examined whether the association between food insecurity and metabolic dysfunction-associated steatotic liver disease (MASLD) differs across different racial/ethnic groups and sex using data from the 2017–March 2020 National Health and Nutrition Examination Survey (NHANES). Methods: A total of 5076 participants aged ≥ 20 years who completed transient elastography examination for evaluation of MASLD were included. Logistic regression, odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate the association of food insecurity with MASLD. Results: Adult food insecurity was associated with increased odds of MASLD (low/very low vs. full security: OR = 1.41, 95% CI 1.12–1.77). Although there was no significant interaction between food insecurity and race/ethnicity ( p interaction = 0.23), the positive association between food insecurity and MASLD was limited among non-Hispanic Whites. Food insecurity was associated with higher odds of MASLD in women but not men, with an interaction between food insecurity and sex ( p interaction = 0.049). Furthermore, mediation analyses suggested that added sugar intake and intake of whole fruits and non-potato vegetables partially mediated the association of food insecurity with MASLD. The partial mediating effects of these foods were observed only among non-Hispanic Whites but not observed in other racial/ethnic groups or across sex. Conclusion: Our results suggest that the positive association between food insecurity and MASLD may be dependent on race/ethnicity and sex. Increased consumption of whole fruits vegetables intake and reduced intake of added sugar may partially reduce the impact of food insecurity on MASLD development.
- 25 May 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 71 (4) , 108434
BMI and Initiation of Cancer Screening: A Closer Look at Differences by Race, Ethnicity, and Sex in a Multicenter Population
- 25 May 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 71 (4) , 108434
BMI and Initiation of Cancer Screening: A Closer Look at Differences by Race, Ethnicity, and Sex in a Multicenter Population
- Open Access
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Aging
- Vol. 6, 1710324
The effect of phenotypic aging on the relationship between cancer history and mortality in US adults
Cancer survivors may have an accelerated biological aging process compared to cancer-free individuals. In this study, we aimed to investigate associations between clinical measures of biological aging and mortality (all-cause, cancer, and cardiovascular disease [CVD]) and examine whether the association between cancer history and mortality is mediated by biological aging. Data from the National Health and Nutrition Examination Survey (NHANES) 1999–2010, with follow-up through 31 December 2019, were used. A total of 1,493 cancer survivors and 4,479 matched non-cancer individuals aged ≥20 years were included. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Biological age (BA) was measured by phenotypic age (PhenoAge) based on nine clinical biomarkers. The mediating effect of biological age was assessed using structural equation models with the bootstrapping method by estimating indirect (IE) and direct (DE) effects from cancer history to mortality. Compared to non-cancer individuals, cancer survivors had accelerated PhenoAge. The association between cancer history and all-cause mortality risk was partially mediated by PhenoAge acceleration (HR IE = 1.02, 95% CI: 1.01–1.03). Accelerated PhenoAge also partially mediated the association between cancer history and cancer-specific mortality (HR IE = 1.06, 95% CI: 1.01–1.18). In particular, PhenoAge acceleration mediated 15.5% and 24.1% of the associations of cancer history with all-cause and cancer-specific mortality, respectively. Our results highlight the importance of decelerating the biological aging process among cancer survivors, which may improve survivorship and long-term health in this population.
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Aging
- Vol. 6, 1710324
Open AccessThe effect of phenotypic aging on the relationship between cancer history and mortality in US adults
Cancer survivors may have an accelerated biological aging process compared to cancer-free individuals. In this study, we aimed to investigate associations between clinical measures of biological aging and mortality (all-cause, cancer, and cardiovascular disease [CVD]) and examine whether the association between cancer history and mortality is mediated by biological aging. Data from the National Health and Nutrition Examination Survey (NHANES) 1999–2010, with follow-up through 31 December 2019, were used. A total of 1,493 cancer survivors and 4,479 matched non-cancer individuals aged ≥20 years were included. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Biological age (BA) was measured by phenotypic age (PhenoAge) based on nine clinical biomarkers. The mediating effect of biological age was assessed using structural equation models with the bootstrapping method by estimating indirect (IE) and direct (DE) effects from cancer history to mortality. Compared to non-cancer individuals, cancer survivors had accelerated PhenoAge. The association between cancer history and all-cause mortality risk was partially mediated by PhenoAge acceleration (HR IE = 1.02, 95% CI: 1.01–1.03). Accelerated PhenoAge also partially mediated the association between cancer history and cancer-specific mortality (HR IE = 1.06, 95% CI: 1.01–1.18). In particular, PhenoAge acceleration mediated 15.5% and 24.1% of the associations of cancer history with all-cause and cancer-specific mortality, respectively. Our results highlight the importance of decelerating the biological aging process among cancer survivors, which may improve survivorship and long-term health in this population.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
Background:Relationships between sleep duration, chronotype, insomnia, and lung cancer risk have not been comprehensively examined. Interrelations between sleep traits on the risk of lung cancer have not been assessed. We aimed to examine sleep traits with lung cancer risk.Methods:Participants were recruited between 2006 and 2010 and followed through November 30, 2020. We included 382,966 participants (3,664 incident lung cancer) in analysis. Cox proportional hazards models estimated HRs and 95% confidence intervals (CI) for associations between sleep duration, chronotype, and insomnia symptoms and lung cancer risk. Joint effects analyses were examined between sleep duration and three traits (chronotype, insomnia, and daytime napping). Nonlinear associations between sleep duration and lung cancer risk were assessed in restricted cubic spline analysis.Results:Longer sleep (>8 hours) was positively associated with lung cancer risk compared with normal sleep duration (7–8 hours; HR = 1.22; 95% CI, 1.10–1.36). Frequent insomnia symptoms increased the risk of lung cancer compared with never/rarely experiencing symptoms (HR = 1.16; 95% CI, 1.05–1.28). Joint effects between sleep duration and chronotype, and sleep duration and insomnia symptoms were observed. In analysis excluding participants reporting shift work at baseline, evening chronotypes (“slight,” “definite”) were at a greater risk of lung cancer compared with definite morning chronotype (HR = 1.17; 95% CI, 1.06–1.28 and HR = 1.37; 95% CI, 1.21–1.54, respectively).Conclusions:Sleep traits such as long sleep duration, frequent insomnia symptoms, and definite evening chronotype may be risk factors for lung cancer. Joint effects should be further investigated.Impact:Sleep traits may be risk factors of lung cancer.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
Background:Relationships between sleep duration, chronotype, insomnia, and lung cancer risk have not been comprehensively examined. Interrelations between sleep traits on the risk of lung cancer have not been assessed. We aimed to examine sleep traits with lung cancer risk.Methods:Participants were recruited between 2006 and 2010 and followed through November 30, 2020. We included 382,966 participants (3,664 incident lung cancer) in analysis. Cox proportional hazards models estimated HRs and 95% confidence intervals (CI) for associations between sleep duration, chronotype, and insomnia symptoms and lung cancer risk. Joint effects analyses were examined between sleep duration and three traits (chronotype, insomnia, and daytime napping). Nonlinear associations between sleep duration and lung cancer risk were assessed in restricted cubic spline analysis.Results:Longer sleep (>8 hours) was positively associated with lung cancer risk compared with normal sleep duration (7–8 hours; HR = 1.22; 95% CI, 1.10–1.36). Frequent insomnia symptoms increased the risk of lung cancer compared with never/rarely experiencing symptoms (HR = 1.16; 95% CI, 1.05–1.28). Joint effects between sleep duration and chronotype, and sleep duration and insomnia symptoms were observed. In analysis excluding participants reporting shift work at baseline, evening chronotypes (“slight,” “definite”) were at a greater risk of lung cancer compared with definite morning chronotype (HR = 1.17; 95% CI, 1.06–1.28 and HR = 1.37; 95% CI, 1.21–1.54, respectively).Conclusions:Sleep traits such as long sleep duration, frequent insomnia symptoms, and definite evening chronotype may be risk factors for lung cancer. Joint effects should be further investigated.Impact:Sleep traits may be risk factors of lung cancer.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
Supplementary Table from Sleep Duration, Chronotype, and Insomnia and the Risk of Lung Cancer: United Kingdom Biobank Cohort
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background:Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers.Methods:A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk.Results:After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers.Conclusions:Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs.Impact:Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background:Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers.Methods:A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk.Results:After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers.Conclusions:Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs.Impact:Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.